Title:
AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/014328
Kind Code:
A3
Abstract:
The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
Inventors:
BOBROWICZ PIOTR (US)
WIDBOOM PAUL (US)
SCHMIDT MICHAEL (US)
LAJOIE JASON (US)
TIGHE ROBERT (US)
LEUNG CHEUK (US)
ESKIOCAK UGUR (US)
WIDBOOM PAUL (US)
SCHMIDT MICHAEL (US)
LAJOIE JASON (US)
TIGHE ROBERT (US)
LEUNG CHEUK (US)
ESKIOCAK UGUR (US)
Application Number:
PCT/US2018/041612
Publication Date:
February 21, 2019
Filing Date:
July 11, 2018
Export Citation:
Assignee:
COMPASS THERAPEUTICS LLC (US)
International Classes:
C07K16/28
Domestic Patent References:
| WO2012032433A1 | 2012-03-15 | |||
| WO2005035584A1 | 2005-04-21 |
Other References:
TIMOTHY S. FISHER ET AL: "Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 61, no. 10, 11 March 2012 (2012-03-11), Berlin/Heidelberg, pages 1721 - 1733, XP055391951, ISSN: 0340-7004, DOI: 10.1007/s00262-012-1237-1
Attorney, Agent or Firm:
MANDRAGOURAS, Amy, E. et al. (US)
Download PDF:
Previous Patent: METHOD TO DETERMINE OPTIMAL MEETING LOCATION AND TIME
Next Patent: CAVITY STABILIZED LASER DRIFT COMPENSATION
Next Patent: CAVITY STABILIZED LASER DRIFT COMPENSATION